One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 1months
-
http://medilib.ir
- Duration of Time : 31 Day
Price : 100$- Special Price : 50$
The dual GLP-1–glucagon agonist pemvidutide in MASH: a phase 2b trial
Why cash transfers matter for global health—now more than ever
Global action on ultra-processed foods: a health, equity, and sustainability imperative
Structural intercompetency: an asylum seeker with abdominal pain in Tijuana, Mexico
Safeguarding research integrity: SAGER guidelines, research ethics, and the politics of evidence
Politicised threats to science endanger global health and humanity
US public health resistance must include Palestine – Author's reply
Population size and vaccination rates for zero-dose estimates – Authors' reply
Eloralintide, a selective amylin receptor agonist, for obesity treatment: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study
The effects of government-led cash transfer programmes on behavioural and health determinants of mortality: a difference-in-differences study
Ultra-processed foods and human health: the main thesis and the evidence
Policies to halt and reverse the rise in ultra-processed food production, marketing, and consumption
Towards unified global action on ultra-processed foods: understanding commercial determinants, countering corporate power, and mobilising a public health response
